Advertisement
New Zealand markets closed
  • NZX 50

    11,946.43
    +143.15 (+1.21%)
     
  • NZD/USD

    0.5936
    -0.0001 (-0.02%)
     
  • NZD/EUR

    0.5546
    -0.0000 (-0.01%)
     
  • ALL ORDS

    7,937.50
    -0.40 (-0.01%)
     
  • ASX 200

    7,683.00
    -0.50 (-0.01%)
     
  • OIL

    82.81
    0.00 (0.00%)
     
  • GOLD

    2,330.10
    -8.30 (-0.35%)
     
  • NASDAQ

    17,526.80
    +55.33 (+0.32%)
     
  • FTSE

    8,040.38
    -4.43 (-0.06%)
     
  • Dow Jones

    38,460.92
    -42.77 (-0.11%)
     
  • DAX

    18,088.70
    -48.95 (-0.27%)
     
  • Hang Seng

    17,201.27
    +372.34 (+2.21%)
     
  • NIKKEI 225

    38,460.08
    +907.92 (+2.42%)
     
  • NZD/JPY

    92.1120
    -0.0030 (-0.00%)
     

Insulet Full Year 2023 Earnings: Beats Expectations

Insulet (NASDAQ:PODD) Full Year 2023 Results

Key Financial Results

  • Revenue: US$1.70b (up 30% from FY 2022).

  • Net income: US$206.3m (up by US$201.7m from FY 2022).

  • Profit margin: 12% (up from 0.4% in FY 2022). The increase in margin was driven by higher revenue.

  • EPS: US$2.96 (up from US$0.066 in FY 2022).

earnings-and-revenue-growth
earnings-and-revenue-growth

All figures shown in the chart above are for the trailing 12 month (TTM) period

Insulet Revenues and Earnings Beat Expectations

Revenue exceeded analyst estimates by 3.0%. Earnings per share (EPS) also surpassed analyst estimates by 48%.

Looking ahead, revenue is forecast to grow 14% p.a. on average during the next 3 years, compared to a 7.8% growth forecast for the Medical Equipment industry in the US.

ADVERTISEMENT

Performance of the American Medical Equipment industry.

The company's shares are down 3.6% from a week ago.

Risk Analysis

You still need to take note of risks, for example - Insulet has 1 warning sign we think you should be aware of.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.